This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Humana (HUM) Brings Home Health Unit of KAH Under CenterWell
by Zacks Equity Research
Humana (HUM) wraps up rebranding KAH's home health operations to the CenterWell brand. This leads to the clubbing of HUM's three payer-agnostic care services into a common suite.
Ensign Group (ENSG) Down 2.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Ensign Group (ENSG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cigna (CI) to Widen Access to Individual Health Plans in 2023
by Zacks Equity Research
Cigna (CI) unveils enhanced individual and family health plans for its customers to opt for in the 2023 Open Enrollment Period. CI will enter newer counties and states to offer better health outcomes.
Teladoc Health (TDOC) Ties Up to Upgrade RPM Care in Canada
by Zacks Equity Research
Teladoc Health (TDOC) teams up with Cloud DX to bring its virtual care capabilities to the latter's platform and dispense advanced RPM solutions to the Canadian residents.
Has BioCardia (BCDA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how BioCardia, Inc. (BCDA) and Ensign Group (ENSG) have performed compared to their sector so far this year.
Here's Why Ensign Group (ENSG) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Ensign Group (ENSG) Stock Up 6% Since Q2 Earnings Release
by Zacks Equity Research
Ensign Group's (ENSG) second-quarter results reflect revenue growth, and solid contributions from the Skilled Services and Standard Bearer segments. A hiked 2022 EPS guidance bodes well.
Here is Why Growth Investors Should Buy Ensign Group (ENSG) Now
by Zacks Equity Research
Ensign Group (ENSG) possesses solid growth attributes, which could help it handily outperform the market.
Ensign Group (ENSG) Meets Q2 Earnings Estimates
by Zacks Equity Research
Ensign Group (ENSG) delivered earnings and revenue surprises of 0% and 0.60%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Ensign Group (ENSG) on a Buyout Binge to Boost US Footprint
by Zacks Equity Research
Ensign Group (ENSG) executes a slew of buyouts to offer better healthcare services to the U.S. residents and further penetrate its operational markets.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Ensign Group (ENSG) Up 3.7% in 30 Days: More Room to Rally?
by Zacks Equity Research
Ensign Group's (ENSG) rising profits from Skilled Services business are a major positive.
Ensign Group (ENSG) Down 5.1% Despite Q1 Earnings Beat
by Zacks Equity Research
Ensign Group's (ENSG) first-quarter results highlight sound contributions from the Skilled Services and Standard Bearer segments, partly offset by a rise in expenses mainly stemming from a higher cost of services.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Ensign Group (ENSG) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Ensign Group (ENSG) delivered earnings and revenue surprises of 3.13% and 1.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Ensign Group (ENSG) Ups Credit Facility to $600M to Fuel Growth
by Zacks Equity Research
Ensign Group (ENSG) expands its credit facility by $250 million to continue with its series of acquisitions, renovation of projects, business requirements et al.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Ensign Group (ENSG) on Buyout Spree, Adds New Properties
by Zacks Equity Research
Ensign Group (ENSG) acquires the operations of certain living facilities in California and Washington to bolster its portfolio.
Zacks Industry Outlook Highlights The Ensign Group, and Brookdale Senior Living
by Zacks Equity Research
The Ensign Group, and Brookdale Senior Living are part of Industry Outlook article.
2 Stocks to Watch From the Promising Nursing Home Industry
by Kaibalya Pravo Dey
The Zacks Medical-Nursing Home industry is set to witness a growing demand from the aging population growth. Ensign Group and Brookdale Senior are poised to benefit from a favorable change in demographics.
Here's Why Ensign Group (ENSG) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Holding Humana (HUM) in Your Portfolio is a Prudent Move
by Zacks Equity Research
Banking on better membership and strategic initiatives, Humana (HUM) holds immense potential to reap benefits for investors.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Humana (HUM) Taps Debt Market With Senior Note Pricing
by Zacks Equity Research
Humana (HUM) exhibits monetary discretion by pricing senior secured notes to procure funds.
Has Ensign Group (ENSG) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Ensign Group (ENSG) and Flora Growth Corp. (FLGC) have performed compared to their sector so far this year.